Markets

OPKO Biologics Doses First Patient In Its Phase 1/2a Clinical Study Of OPK-8801001 To Treat Acromegaly

Oct 27, 2026 · 08:07 AM ET· updated 1h ago

OPKO Biologics Ltd., an OPKO Health company (NASDAQ: OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial of OPK-8801001, an investigational, long acting human

Why It Matters

OPKO started testing a new medicine for a hormone condition. When companies test new drugs, watch if they share good or bad results later.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

OPK1.62

-0.01 (-0.61%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.